IFEG 20353
INSTITUTO DE FISICA ENRIQUE GAVIOLA
Unidad Ejecutora - UE
artículos
Título:
[177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies
Autor/es:
P. AUDICIO; G. CASTELLANO; M. TASSANO; M.E. REZZANO; M. FERNÁNDEZ; E. RIVA; A. ROBLES; P. CABRAL; H. BALTER; P. OLIVER
Revista:
APPLIED RADIATION AND ISOTOPES
Editorial:
PERGAMON-ELSEVIER SCIENCE LTD
Referencias:
Lugar: Amsterdam, Holanda; Año: 2011 vol. 69 p. 924 - 928
ISSN:
0969-8043
Resumen:
Anti-CD20 (Rituximab®), a specific chimeric monoclonal antibody used in CD20-positive Non-Hodgkins Lymphoma, was conjugated to a bifunctional quelate (DOTA) and radiolabeled with 177Lu through a simple method. [177Lu]-DOTA-anti-CD20 was obtained with a radiochemical purity higher than 97%, and showed good chemical and biological stability, maintaining its biospecificity to CD20 antigens. MonteCarlo simulation showed high doses deposited on a spheroid tumor mass model. This method shows to be an appropiate alternative for the production of [177Lu]-DOTA-anti-CD20 as therapeutic radiopharmaceutical.
